A phase 1 study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.

Trial Profile

A phase 1 study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs Gemcitabine; Temsirolimus
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2011 Company (Pfizer) added as trial sponsor as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Planned number of patients changed from 30 to 5 as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top